Be the first to like this
Belviq(Belviq) is a new FDA approved long term weight-loss drug developed by Arena Pharmaceuticals and launched in the US Market as of today, June 06/11/2013. It has serotonergic properties and acts as an anorectic.
Where to be evaluated for Belviq: Belviq is a prescription only weight loss medication and has to be evaluated by a trained and licensed physician familiar with obesity and the treatment of obesity. If you live close a W8MD medical weight loss center location, you may want to consider visiting the closest w8md center to be evaluated to see if Belviq, Qsymia or other weight loss medications or non medication VLCD or LCD diet might be right for you.
How Can W8MD Help?
W8MD Medical Weight Loss Centers Of America announces that Belviq will be offered along with a low calorie diet at its medical weight loss lcoations under the supervision of a trained obesity medicine physician. With offices in many states including New York, Pennsylvania, and Connecticut, W8MD can help you lose weight safely and effectively using non-surgical weight loss measures such as FDA approved weight loss medications, Very Low Calorie and Low Calorie Diets, along with instructions on proper physical activity, you can lose weight safely and effectively.
Price of Belviq
Arena (ARNA) has disclosed that the wholesale price for its anti-obesity drug Belviq is $199.50 for a 60 count bottle (a 1 month supply)
Information on Belviq and Qsymia - Two New Weight Loss Medications
To help obese and overweight Americans who have been unsuccessful in getting their weight under control with diet and exercise, the Food and Drug Administration (FDA) has approved two new medications—the first drugs for long-term weight management that FDA has approved in 13 years.
Marketed as Belviq and Qsymia, these prescription medications would be taken for the rest of a person’s life. “For many people, obesity is a lifelong condition, but we don’t always think of it—or treat it—as such,” says Amy Egan, M.D., M.P.H., deputy director for safety in FDA’s Division of Metabolism and Endocrinology Products (DMEP).
“Qsymia and Belviq are considered life-long therapies in patients who respond to and tolerate them,” says Egan.
The drugs are meant to be used in conjunction with a balanced diet and exercise, says Mary Roberts, M.D., a medical officer in DMEP. “These drugs are another tool to be used by someone trying to reach and stay at a healthy weight,” she says.
Are You a Candidate?
You may be a candidate for taking Belviq or Qsymia if you are at least 18 and:
• your body mass index (BMI) is 30
or greater (obese); or
• your BMI is 27 or greater
(overweight) and you have at
least one other weight-related
Women who are pregnant or thinking of becoming pregnant should not take either of these medications, Egan say s, because weight loss offers no potential benefit to a pregnant woman and can cause fetal harm.